NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Diagnostics & Research · USD

ICON Public Limited Company (ICLR) Stock Analysis

ICON Public Limited Company (ICLR) is a Diagnostics & Research stock listed on NASDAQ and quoted in US Dollar.

ICLR

$164.85

+$1.27 (+0.78%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare ICLR with… →

ICLR Key Statistics

As of Sep 4, 2026
Trading
Open
$159.94
Previous Close
$163.58
Day's Range
159.50–165.92
52-Week Range
66.57–203.91
Volume
796.40K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.20
Valuation
Market Cap
$12.72B
P/E Ratio
249.77
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
13.88
PEG RatioThe P/E ratio divided by the expected earnings growth rate. It puts a high P/E in the context of how fast profits are growing.
0.50
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
1.53
EPS (ttm)Profit attributable to each share over the last twelve months.
0.66
Financials (FY)
Revenue (FY)
$8.25B+0.76%
Net Income (FY)
$229.34M−68.97%
Profit marginThe share of revenue left as profit after all costs and taxes.
0.33%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
77.15M
1-Year Return
−6.53%
Dividend and dates
Earnings Date
October 21, 2026estimated
Avg Volume
804.76K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

ICLR Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−9.53%
2025−13.11%
2024−25.92%
2023+45.72%
2022−37.28%
2021+58.84%
2020+13.21%
2019+33.29%
2018+15.21%
2017+49.14%
2016 (partial year)−0.21%

As of September 4, 2026.

ICLR Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$8.25B$229.34M2.8%
2024$8.19B$739.13M9.0%
2023$8.05B$554.21M6.9%
2022$7.74B$505.30M6.5%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$8.25B$2.18B$1.01B$229.34M2.8%
2024$8.19B$2.37B$1.15B$739.13M9.0%
2023$8.05B$2.35B$994.23M$554.21M6.9%
2022$7.74B$2.21B$866.08M$505.30M6.5%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

ICLR Valuation vs Diagnostics & Research Median

Median of 49 stocks
MetricICLRDiagnostics & Research medianvs median
P/E249.7733.087.6x the median
P/S ratio1.534.990.3x the median
Profit margin0.33%0.00%0.3 pts above

Medians across 49 Diagnostics & Research stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

All 14 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

ICON Public Limited Company (ICLR) carries a market capitalisation of $12.72B. The company sits in the Healthcare sector, in the Diagnostics & Research industry. The company reports 40,200 employees.

The 52-week range on file runs from $66.57 to $203.91. ICLR last closed at $164.85 on September 4, 2026. That is +$1.27 (+0.78%) against the previous close. The latest close sits 147.63% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $8.25B. Against the prior fiscal year total of $8.19B, that is a change of +0.76%. The same year closed with net income of $229.34M. That is −68.97% against the prior fiscal year. The reported profit margin is 0.33%. That is 0.3 percentage points above the Diagnostics & Research median of 0%. Earnings per share on a trailing basis come to 0.66.

Across the 4 fiscal years on file, revenue moves from $7.74B in 2022 to $8.25B in 2025. Of those 4 years, 4 report positive net income.

Valuation Assessment

On trailing earnings, the shares are priced at 249.77 times earnings. That is 7.6 times the Diagnostics & Research median of 33.08. On forward earnings the ratio is 13.88. The PEG ratio, which sets the P/E against expected earnings growth, reads 0.5. Measured against sales, the shares trade at 1.53 times revenue. On price-to-sales that is 0.3 times the Diagnostics & Research median of 4.99. The medians here are taken across 49 Diagnostics & Research companies that report the metric.

Over the trailing twelve months the price has returned −6.53%. Across 10 years the annualized return works out at +7.89%. The reported beta is 1.2. Annualized volatility over the trailing 10 years is 38.23%.

Growth & Income

No dividend is on file for ICLR.

So far in 2026 the price is −9.53%. The strongest complete calendar year on file is 2021 at +58.84%; the weakest is 2022 at −37.28%. Of the 9 complete calendar years on file, 6 finished higher.

Peer Comparison

ICON Public Limited Company (ICLR) operates in the Diagnostics & Research industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
ICON Public Limited Company ICLR $12.72B 249.8
Thermo Fisher Scientific Inc. TMO $226.94B 33.0
Danaher Corporation DHR $145.98B 37.0
Natera, Inc. NTRA $47.31B —

The Diagnostics & Research industry average P/E ratio is 33.1x. ICON Public Limited Company trades at a P/E of 249.8.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Diagnostics & Research Stocks

TMO

Thermo Fisher Scientific Inc.

$226.94B

 DHR

Danaher Corporation

$145.98B

 NTRA

Natera, Inc.

$47.31B

 IQV

IQVIA Holdings Inc.

$44.07B

 A

Agilent Technologies, Inc.

$42.54B

 IDXX

IDEXX Laboratories, Inc.

$42.18B
View all Diagnostics & Research stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About ICON Public Limited Company

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It also provides clinical development services, including all phases of development, peri and post approval, data solutions, and site and patient access services; clinical trial management, consulting, contract staffing, data solutions, and laboratory services; and commercial services comprising clinical development strategy, planning and trial design, full study execution, and post-market commercialization. In addition, the company offers testing services comprising bioanalytical, biomarker, vaccine, good manufacturing practice, and central laboratory services, as well as full-service and functional service partnerships to customers. Further, the company provides adaptive trials, cardiac safety solutions, clinical and scientific operations, consulting and advisory, commercial positioning, decentralized and hybrid clinical trials, early clinical, medical imaging, real world intelligence, site and patient, and strategic solutions. Additionally, it provides therapeutics for cardiovascular, central nervous system, endocrine and metabolic disorders, hepatology, infectious diseases, internal medicine immunology, and oncology. It serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. ICON Public Limited Company was incorporated in 1989 and is headquartered in Dublin, Ireland.

Visit website →